Kiniksa Pharmaceuticals International Plc’s recent filing unveils that its CHIEF COMMERCIAL OFFICER Moat Ross unloaded Company’s shares for reported $0.18 million on May 05 ’25. In the deal valued at $28.00 per share,6,272 shares were sold. As a result of this transaction, Moat Ross now holds 9,415 shares worth roughly $0.25 million.
Then, Moat Ross sold 3,850 shares, generating $107,800 in total proceeds. Upon selling the shares at $28.00, the CHIEF COMMERCIAL OFFICER now owns 9,415 shares.
Before that, Moat Ross bought 6,272 shares. Kiniksa Pharmaceuticals International Plc shares valued at $175,646 were divested by the Officer at a price of $28.00 per share.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -3.02% to $26.94. Over the last five days, the stock has gained 4.10%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 36.20% since the year began. Nevertheless, the stocks have risen 39.01% over the past one year. While a 52-week high of $28.56 was reached on 05/05/25, a 52-week low of $17.38 was recorded on 01/13/25. SMA at 50 days reached $22.06, while 200 days put it at $22.71.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 26.43, which if violated will result in even more drops to 25.92. On the upside, there is a resistance level at 27.58. A further resistance level may holdings at 28.22. The Relative Strength Index (RSI) on the 14-day chart is 70.16, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.02, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.12%. Stochastics %K at 89.25% indicates the stock is a selling.
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
